Introduction
The quinolones inhibit the essential bacterial enzymes DNA gyrase and topoisomerase IV, which alter DNA topology after inserting a double-stranded break. 1 DNA gyrase exists as an A 2 B 2 tetramer, encoded by the gyrA and gyrB genes, and catalyses negative DNA supercoiling. 2 Topoisomerase IV exists as a C 2 E 2 tetramer encoded by the parC and parE genes, and is involved in chromosome partitioning. 3 Previous studies have shown that the quinolones are stronger inhibitors of pneumococcal topoisomerase IV than of pneumococcal DNA gyrase. 4, 5 Furthermore, for Streptococcus pneumoniae the MICs of quinolones correlate well with the topoisomerase IV IC 50 but not so well with the DNA gyrase IC 50 . 4 Hence, topoisomerase IV appears to be the most likely primary target for quinolones in S. pneumoniae. 4 Gemifloxacin is a novel quinolone derivative with potent in vitro activity, particularly against S. pneumoniae. 6 It is active against ciprofloxacin-and trovafloxacin-resistant pneumococci. 7, 8 This study was carried out to investigate the molecular basis of the enhanced anti-pneumococcal activity of gemifloxacin compared with other quinolones.
Materials and methods

Antimicrobial agents
Gemifloxacin, trovafloxacin, levofloxacin, ciprofloxacin and grepafloxacin were provided by SmithKline Beecham Pharmaceuticals (Harlow, UK). Moxifloxacin was provided by Bayer AG (Wuppertal, Germany). All antibiotic solutions were freshly prepared on each day of the study.
Bacterial strains
The following three strains of S. pneumoniae were investigated in this study: (i) C3LN4, a ciprofloxacin-sensitive laboratory strain used previously as a source of pneumococcal topoisomerases. 4 The MICs of gemifloxacin, ciprofloxacin, levofloxacin, grepafloxacin, moxifloxacin and trovafloxacin for this strain were 0.06, 2, 1, 0.5, 0.12 and 0.06 mg/L, respectively. (ii) 502226, a ciprofloxacin-resistant clinical isolate from the Alexander Project culture collection. 9 It contains amino acid changes Ser81ǞPhe in GyrA, Asp83ǞAsn in ParC and Ile460ǞVal in ParE. 10 The MICs of gemifloxacin, ciprofloxacin, levofloxacin, grepafloxacin, moxifloxacin and trovafloxacin for this strain were 0. 10 The MICs of gemifloxacin, levofloxacin, grepafloxacin, moxifloxacin and trovafloxacin for this strain were 0.5, 16, 16, 4 and 8 mg/L, respectively.
Bacteria were stored at -70°C and subcultured on to Mueller-Hinton agar (Unipath, Basingstoke, UK) supplemented with 5% (v/v) saponin-lysed horse blood (Unipath) before use.
MIC tests
Quinolone MICs were determined by the NCCLS microbroth dilution technique in Mueller-Hinton broth supplemented with 2% (v/v) lysed horse blood.
11
PCR cloning of topoisomerase genes for protein purification
Chromosomal DNA was obtained from each strain after lysis by boiling, phenol/chloroform extraction and precipitation with ethanol. It was then used as a template for PCR. Oligonucleotide primers for parC, parE, gyrB and gyrA were designed according to published sequences. 12, 13 The reaction conditions used for PCR were identical to those previously described. 4 After PCR, amplified DNA was treated with T4 DNA polymerase (New England Biolabs UK Ltd, Hitchin, UK) followed by T4 polynucleotide kinase (New England Biolabs UK Ltd) according to the manufacturer's instructions.
Construction of overexpressing Escherichia coli
Topoisomerase subunit PCR products were inserted separately into XmnI-cut pMAL-c2 protein fusion vector using T4 DNA ligase (New England Biolabs UK Ltd). This positioned each topoisomerase subunit gene adjacent to the malE gene, which encodes the maltose-binding protein.
Purified vector DNA containing separate topoisomerase genes was used to transform competent E. coli DH5␣. Transformants were selected on agar plates containing 50 mg/L ampicillin. Clones that overproduced the protein of interest (i.e. topoisomerase subunit) fused to the maltose-binding protein were selected by choosing those isolates that appeared to overproduce a protein of the expected size of the fusion protein as shown by SDS-PAGE.
Purification of topoisomerase subunits
Cloned E. coli were inoculated into Luria-Bertani broth (Unipath) containing 50 mg/L ampicillin. Cultures were incubated at 37°C overnight with shaking, and then induced with isopropyl -D-thiogalactoside (IPTG) to overproduce the fusion protein. Bacteria were harvested by centrifugation and washed three times in buffer consisting of 20 mM Tris-HCl (pH 7.4), 200 mM NaCl and 1 mM EDTA. Bacteria were then lysed by the addition of lysozyme followed by three repeated freeze-thawing steps. The lysed bacterial suspension was centrifuged and the supernatant was loaded on to an amylose resin affinity chromatography column. Bound fusion protein was then eluted with 10 mM maltose. The GyrA, GyrB, ParC or ParE proteins were cleaved from the fusion protein by factor Xa digestion at 23°C overnight. The separated maltose-binding protein was removed by further amylose column chromatography.
Quinolone inhibition of topoisomerase IV
Reaction mixtures (20 L) were set up to contain 0.4 g kinetoplast DNA (Topogen Inc., Columbus, OH, USA), 40 mM Tris-HCl, 20 mM KCl, 5 mM MgCl 2 , 50 mg/L bovine serum albumin (BSA), 1 mM dithiothreitol (DTT), 0.5 mM ATP and one unit of topoisomerase IV (defined as the amount of reconstituted ParC and ParE required to decatenate 0.4 g kinetoplast DNA in 1 h at 37°C). After incubation with various concentrations of the study quinolones at 37°C for 1 h, reactions were stopped by the addition of 5 L stopping solution (5% (v/v) sarkosyl, 25% (v/v) bromophenol blue and 25% (v/v) glycerol). The samples were then subjected to 1% agarose gel electrophoresis, and the intensity of the decatenated DNA band was analysed using the Gel Doc 1000 system (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK). Inhibition of topoisomerase IV was expressed as a percentage of the intensity of the decatenated band compared with a drug-free control. The average of triplicate experiments was used to plot percentage decatenation against quinolone concentration. The quinolone concentration required to inhibit enzyme activity by 50% (IC 50 ) was estimated from these plots.
Inhibition of DNA gyrase by quinolones
Reaction mixtures (20 L) were set up to contain 20 mM Tris-HCl, 20 mM KCl, 8 mM MgCl 2 , 25 mg/L BSA, 1 mM DTT, 5 mM ATP, 5 mM spermidine, 2.5 g tRNA, 0.2 g relaxed pBR322 DNA and one unit of DNA gyrase (defined as the amount of reconstituted enzyme required to supercoil 0.2 g relaxed DNA in 1 h at 37°C). After incubation with various concentrations of the test agents at 37°C for 1 h, reactions were stopped and analysed as described for topoisomerase IV. For DNA gyrase inhibition, IC 50 values were calculated by comparing the intensity of supercoiled DNA bands.
Results
Purification of topoisomerases
The specific activities of the reconstituted topoisomerase subunit proteins selected by SDS-PAGE are shown in Table I . It can be seen that the enzymes from ciprofloxacinresistant S. pneumoniae (strains 503244 and 502226) were generally slightly less active than the enzymes from the ciprofloxacin-sensitive strain (C3LN4). As these specific activities were similar to those described previously, 4 the small differences in activity between the purified enzymes is not likely to affect quinolone inhibition.
Inhibition of topoisomerase IV and DNA gyrase
The inhibition of topoisomerase IV from S. pneumoniae C3LN4 by ciprofloxacin and gemifloxacin is shown in Figure 1 . From these plots IC 50 values were calculated, and gemifloxacin was found to be approximately five times as active as ciprofloxacin. The results for inhibition of DNA gyrase from S. pneumoniae C3LN4 by ciprofloxacin and gemifloxacin are shown in Figure 2 . It can be seen that the IC 50 values for inhibition of DNA gyrase were at least ten times higher than those required to inhibit topoisomerase IV. These results indicate that, as for all other quinolones, topoisomerase IV is the primary target for gemifloxacin in S. pneumoniae. Data for all quinolones against DNA gyrase and topoisomerase IV from all three pneumococci are summarized in Table II . These data show that gemifloxacin was the strongest inhibitor of topoisomerase IV from the ciprofloxacin-sensitive pneumococcus and from the two ciprofloxacin-resistant strains. All the quinolones, except ciprofloxacin, showed very similar IC 50 values against DNA gyrase from S. pneumo- niae C3LN4 (Table II) . The IC 50 values for ciprofloxacin and levofloxacin against DNA gyrase and topoisomerase IV were very similar to those found previously. 4 When inhibition of DNA gyrase from S. pneumoniae 502226 was investigated, grepafloxacin and trovafloxacin showed stronger activity than gemifloxacin. However, gemifloxacin and trovafloxacin were, jointly, the most potent compounds against DNA gyrase from S. pneumoniae 503244.
The data presented in Table II clearly indicate that, for all three pneumococcal strains tested, quinolone activity was at least four times greater against topoisomerase IV than against DNA gyrase. Of the compounds tested, gemifloxacin had the highest differential activity between the two enzymes. In addition, when DNA gyrase or topoisomerase IV IC 50 was plotted against MIC, a better correlation was found between topoisomerase IV IC 50 than DNA gyrase IC 50 (Figure 3) . It would appear, therefore, that topoisomerase IV is the most likely primary target in S. pneumoniae for quinolones.
Discussion
The results of this study provide further confirmation of earlier findings suggesting that topoisomerase IV is the primary target for quinolones against S. pneumoniae. 4 Other researchers have also investigated quinolone inhibition of DNA gyrase and topoisomerase IV from S. pneumoniae using cleavable complex formation rather than IC 50 as the assay endpoint. 5 This study also showed that topoisomerase IV, rather than DNA gyrase, was the primary target for quinolones in S. pneumoniae. 5 We have shown elsewhere 8 that gemifloxacin had the lowest MIC and was the most bactericidal quinolone for the three pneumococci used in this study. From the topoisomerase IC 50 data presented here, it seems likely that the potent antipneumococcal activity of gemifloxacin results from its potent activity against pneumococcal topoisomerase IV. Only sitafloxacin has been shown to have such a low IC 50 against topoisomerase IV from S. pneumoniae C3LN4. 4 Surprisingly, the inhibition of DNA gyrase by gemifloxacin was no greater than that recorded for the other quinolones tested. This is in contrast to sitafloxacin, which has equal potency against DNA gyrase and topoisomerase IV. 4 When inhibition of topoisomerases from the two ciprofloxacin-resistant strains was investigated, it was found that these enzymes were two-to seven-fold less susceptible to quinolones than the enzymes from S. pneumoniae C3LN4. The susceptibility of DNA gyrases from S. pneumoniae 502226 and 503244 to gemifloxacin, ciprofloxacin or moxifloxacin was similar (within 10%); this is to be expected since sequencing of the quinolone resistance-determining regions (QRDRs) of the DNA gyrase genes from both strains show the same mutation, leading to a Ser81ǞPhe change within GyrA. 10 However, levofloxacin, grepafloxacin or trovafloxacin were more active (by 26-49%) against DNA gyrase from S. pneumoniae 502226 than against gyrase from S. pneumoniae 503244. These results suggest that DNA gyrase from S. pneumoniae 502226 may be hypersusceptible to levofloxacin, grepafloxacin or trovafloxacin. Such hypersusceptibility has been noted previously with gyrB mutations in E. coli.
14 Another explanation might be that DNA gyrase from S. pneumoniae 503244 is more resistant to the action of these quinolones than that from S. pneumoniae 502226. Whichever is the case, the effect would result from a mutation outside the perceived QRDRs for S. pneumoniae. Sequencing of the whole of the gyrA and gyrB genes from S. pneumoniae, in addition to the parC and parE genes, would allow investigation of the presence of mutations outside what is currently thought to be the QRDR. It is also possible that a mutation or mutations outside proposed QRDRs may have led researchers to suggest incorrectly that DNA gyrase is the primary target for sparfloxacin. 4 In both ciprofloxacin-resistant pneumococci, the topoisomerase IV IC 50 remained lower than DNA gyrase IC 50 . IC 50 values against topoisomerase IV from S. pneumoniae 503244 were, for the most part, higher than those against topoisomerase IV from S. pneumoniae 502226. This can be explained by the fact that S. pneumoniae 503244 contains one more mutation within parC than S. pneumoniae 502226. However, this phenomenon was not universal. For example, trovafloxacin was equally active against topoisomerase IV from both strains. This again suggests that mutations within topoisomerases may affect the action of trovafloxacin differently from the action of other quinolones or indeed that unknown mutations outside the QRDRs may play a role in defining IC 50 . The most notable exception to the relative inhibition of topoisomerase IV was grepafloxacin, which showed greater activity against topoisomerase IV from S. pneumoniae 502226 than against that from S. pneumoniae 503244. This, however, did not correlate with the grepafloxacin MIC or bactericidal index for these strains. 8 The difficulty in comparing enzyme assays and MIC or bactericidal activity for bacteria lies in the involvement of additional factors associated with intact bacteria, such as quinolone efflux mechanisms. Both S. pneumoniae 502226 and 503244 have been shown to possess an efflux mechanism for some, but not all, of the quinolones used in this study. Interestingly, efflux was not observed with grepafloxacin. 10 To analyse the effect of topoisomerase mutations fully, isogenic strains of S. pneumoniae could be prepared that vary only by the single point mutations implicated in quinolone resistance. Purification of the topoisomerases from these strains and inhibition by quinolones would aid in understanding the mechanism of action of quinolones. Furthermore, crystallographic data from such enzymes would provide crucial information, enabling differences between quinolones to be appreciated fully.
